Save up to 76% on select services through 12/31!

Save up to 76% on select services through 12/31!

Want to know more?: Download the Free Info Guide

24/7 Support: (404) 315-6500

Stem Cell Expansion on the Rise

Mount Sinai Receives $8.8 million Grant to Further Stem Cell Research An $8.8 million grant from the New York State Stem Cell Science Program will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem-cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders. New York -Article from www.mountsinai.org- […]

Mount Sinai Receives $8.8 million Grant to Further Stem Cell Research

An $8.8 million grant from the New York State Stem Cell Science Program will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem-cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders.

New York
-Article from www.mountsinai.org-

 – April 7, 2015 /Press Release/  –– 

An $8.8 million grant from the New York State Stem Cell Science Program (NYSTEM) will accelerate efforts by the Icahn School of Medicine at Mount Sinai (ISSMM) to develop new stem-cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders. Specifically, the grant is expected to advance on-going research efforts seeking to increase the number of stem cells in cord blood collections.

Blood stem cell transplantation is the only potential therapy available for most patients with blood cancers. To obtain blood stem cells for transplant, doctors use cord blood collections which contain only limited numbers of stem cells.  Mount Sinai researchers have developed a method to increase the number of collected stem cells 35-fold. The grant will move this research ahead to clinical trials in collaboration with biotechnology firms NeoStem and AllCells, leaders in cellular therapy.

Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine, Hematology and Medical Oncology, Professor of Gene and Cell Medicine, and Director of the Myeloproliferative Disorders Research Program, ISSMM, will head this research project. Dr. Hoffman has been a leader in stem cell research and his earlier observation of myeloproliferative neoplasms and the biology of human hematopoietic stem cells and progenitor cells have led to therapeutic trials to improve therapy of this disease.

“We are grateful to NYSTEM for providing a unique opportunity to move our discoveries in the laboratory to a clinical setting,” said Dr. Hoffman. “We are able to build upon 30 years of work to develop new treatment options for our patients.”

“This award creates a synergistic environment between academic centers and biotechnology firms. And ensures promising research continues to keep progressing,” said Dr. Hoffman. “Our partners NeoStem and AllCells are vital contributors in this next phase of research. We are very excited about the journey ahead.”

Follow this link to view AlphaCord’s blog post and see a few benefits of cord blood and tissue storage.

 

THE CONTENT OF THIS ARTICLE DOES NOT PROVIDE MEDICAL ADVICE.  It is intended for general informational purposes only and is not a substitute for professional medical advice or treatment. If you have a medical emergency or question, immediately call your doctor or dial 911 for assistance.

Ready to sign
up now?

Take advantage of this once-in-a-lifetime opportunity and speak to one of our newborn stem cell educators today to receive our
latest offers.

Call now
Closeup of a couple embracing the mother’s pregnant belly.